According to the study, in age group of people under 60, the Russian drug efficacy exceeds 75 percent, while in severe cases and hospitalization it is even higher.
Gamaleya stated that its impact on the Delta strain surpasses that of numerous foreign two-component vaccines, which show a significant decrease in efficacy to less than 50 percent five months after vaccination.
The drug is the first component of the two-dose Covid-19 vaccine Sputnik V, registered in 70 countries covering a population of more than four billion people.
Sputnik Light has been approved for the treatment of the disease in more than 15 nations and in another 30 it is in the process of being registered. The National Center for Epidemiology and Microbiology assured that it is a universal booster for other vaccines.
‘Positive data from clinical trials in Argentina and other countries show the safety and high immunogenicity of Sputnik Light as a booster for drugs from other producers’, the Center stated.
Analyzes carried out, the report indicated, tell that as a supplement its efficacy against the Delta variant will be more than 83 percent against infection and more than 94 percent against hospitalization cases.
This Wednesday, the Direct Investment Fund and the Gamaleya Center announced the publication on MedRxiv scientific articles on medicine portal of results of the study of the vaccination efficacy of Sputnik-Light against the Delta variant of the SARS-CoV-2 coronavirus.